Journal
NEURODEGENERATIVE DISEASE MANAGEMENT
Volume -, Issue -, Pages -Publisher
FUTURE MEDICINE LTD
DOI: 10.1177/17562864211058298
Keywords
cladribine tablets; clinical research; COVID-19; lay summary; multiple sclerosis; plain language summary; vaccination
Categories
Funding
- Merck Healthcare KGaA, Darmstadt, Germany [10.13039/100009945]
Ask authors/readers for more resources
This summary discusses the findings from a previously published article that provides recommendations for COVID-19 vaccinations in multiple sclerosis (MS) patients taking cladribine tablets. The results suggest that MS patients taking cladribine tablets should receive the COVID-19 vaccine as soon as possible, as it is considered safe and effective without interference from the medication.
What is this summary about? People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsingremitting or active secondary progressive disease) taking cladribine tablets. What were the results? The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets. What do the results mean? Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available